Global Non-Invasive Prenatal Testing Market: Rising Average Maternal Age Worldwide to Fuel Market at 17.50% CAGR

Over the decade, the global non-invasive prenatal testing (NIPT) has shown a healthy growth. The rise in the global average of maternal age, coupled with the increasing incidence of Down syndrome in newborns, has boosted the market to a significant level. Additionally, the augmenting demand for timely and non-invasive fetal diagnosis is anticipated to propel the market in the coming years.

The global NIPT market is analyzed on the basis of the tests and the regional distribution of this market. Based on tests, the market is broadly classified into BambniTest, informaSeq, Harmony, MaterniT21 PLUS, Panorama, NIFTY, PrenaTest, VisibiliT, and verifi. Regionally, the worldwide market for NIPT is distributed among North America, Asia Pacific, Europe, and the Rest of the World.

The report present a comprehensive study of the global NIPT market with an analytical approach. Market drivers, restraints, opportunities, current and upcoming trends, and various segmentations of this market has been discussed at length in this study, making it a valuable source of guidance for market participants.

Overview of the Global NIPT Market

The global NIPT market stood at US$0.5 bn in 2013. Expanding at a CAGR of 17.50% over the period from 2014 to 2022, the market is projected to reach US$2.38 bn by the end of the forecast period.

According to the report, the first non-invasive prenatal test launched in the market was MaterniT21 PLUS. The test was introduced in 2011 and was intended to diagnose trisomy 21. In 2013, the market for MaterniT21 PLUS accounted for 36.1% of the total revenue generated in the NIPT market across the globe. However, this market segment is likely to lose ground on account of rising commercialization of panorama, Verifi, Bambni, and NIFTY during the forecast period.

The NIPT market in North America emerged as the largest regional market of the global NIPT market in 2013 with a 58.8% share in terms of revenue and a 51% share in terms of volume. The presence of major market participants in the U.S. and a high level of awareness pertaining to NIPT in North America has boosted the regional market extensively.

The Asia Pacific NIPT market is showing immense potential for growth. Australia, Japan, India, and China are the key markets for NIPT in this region. A large population base of women choosing late pregnancy is expected to drive the Asia Pacific market for NIPT market over the forecast period.

The presence of untapped opportunities in developing economies across the globe provides a huge potential market for participants. However, the strict regulatory guidelines regarding non-invasive prenatal testing and the availability of alternative screening and testing procedures are likely inhibit the growth of the market to an extent.

Download Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

Companies mentioned in the research report

Laboratory Corporation of America Holdings, Berry Genomics Co. Ltd., Illumina Inc., LifeCodexx AG, Sequenom Inc., BGI Diagnostics, Ariosa Diagnostics Inc., and Natera Inc. are the major companies functioning in the global NIPT market. Strategic partnership and alliance with hospitals, medical research centers, and clinical laboratories are the key trends among the market participants for the expansion of their business.

Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022

According to a new market report published by Transparency Market Research “Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022”, the global NIPT market was valued at USD 0.53 billion in 2013 and is expected to expand at a CAGR of 17.5% from 2014 to 2022 to reach USD 2.38 billion in 2022.

Non-invasive prenatal diagnosis refers to screening test recommended for the detection of certain specific chromosomal aneuploidies from maternal blood sample. Over the past two years, the global prenatal testing market has witnessed a paradigm shift from conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS) to non-invasive prenatal testing. This was mainly because of the advantages associated with NIPTs such as safety, accuracy, and no risk of miscarriage during the genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.). Currently, NIPTs are recommended only to high-risk pregnant women; however, several companies are targeting their tests toward both low-risk and high-risk pregnancies.

Browse Full Report: http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html

BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, and VisibiliT are the commercially available NIPTs in the global market. These tests are based on the direct analysis of cell-free fetal DNA in the maternal blood. MaterniT21 (MaterniT21 PLUS) was the first non-invasive prenatal Laboratory Developed Test (LDT) that was launched by Sequenom, Inc. in October 2011 for the detection of trisomy 21. MaterniT21 PLUS gained advantage of being the first mover in the NIPT market and was the most accepted NIPT in 2013, accounting for 36.1% share of the market in terms of revenue. It is likely to lose market share during the forecast period from 2014 to 2022 due to increasing market penetration by other NIPTs such as NIFTY, Panorama, and verifi.

In terms of volume, MaterniT21 test was the leading segment in 2013. However, the number of MaterniT21 tests performed would decrease during the forecast period from 2014 to 2022. This is majorly due to commercialization of other non-invasive tests and their positioning strategies. Due to the recent CFDA approval for BambniTest (Berry Genomics), the number of tests performed would increase during the forecast period.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

Advantages offered by NIPT such as non-invasiveness, high accuracy and early detection; rising awareness, increasing market penetration in highly untapped countries in Europe and Asia; and continuous increase in average maternal age are the major factors expected to drive the growth of the global NIPT market during the forecast period. However, the market could face significant ethical and regulatory hurdles associated with the implementation of NIPT because of the belief that it is likely to increase the incidence of abortions. Therefore, various professional organizations such as the American College of Obstetricians and Gynecologists (ACOG), the International Society for Prenatal Diagnosis, the Japan Society of Obstetrics and Gynecology, and genetic counselors across the world have set up guidelines that limit the use of non-invasive prenatal testing only to pregnant women at high risk of chromosomal aneuploidies.

Several companies are investing in the development of non-invasive prenatal tests. Quest Diagnostics is developing a non-invasive test by utilizing the patented technology of Sequenom, Inc. and the test is likely to be commercialized in 2015. Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera, Inc., BGI Diagnostics, LifeCodexx AG, LabCorp, and Berry Genomics are the major companies operating in the global non-invasive prenatal tests market.

Browse the full Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and Others) - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022 Press Release at http://www.transparencymarketresearch.com/pressrelease/noninvasive-prenatal-diagnostics-market.htm

The global non-invasive prenatal testing market is segmented as follows:

Global Non-invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Test

• BambniTest
• Harmony
• informaSeq
• MaterniT21 PLUS
• NIFTY
• Panorama
• PrenaTest
• verifi
• VisibiliT

Global Non-invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.